MyoGene Bio, LLC

About MyoGene Bio, LLC

MyoGene Bio is committed to developing cutting-edge therapies for muscle diseases, with a mission to significantly impact disease progression for devastating muscle disorders.

Products & Services

MyoDys45-55:A gene editing treatment designed to permanently address the underlying cause of Duchenne muscular dystrophy for half of all patients using a single platform.

Specialties

Gene Editing Muscle Disease Therapies Duchenne Muscular Dystrophy Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Capital T: - FT: Venture Capital	A: 400000 MR: - FA: $400,000 FAN: 400000	D: 2025-11-04 FD: 2025-11-04	3 investors

Venture Capital Latest

2025-11-04

$400K

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Courtney Young

CEO, Co-founder

M

Melissa Spencer

Scientific Advisor, Co-founder

A

April Pyle

Scientific Advisor, Co-founder

C

Christopher

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

MyoGene Bio, LLC Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised